VPB1305 - Сarrying out stem cell autotransplantation without cryo-freezing

Background: In the Center of Hematology (Uzbekistan) in 2021, 31 autologous transplantations of hematopoietic blood stem cells (HSCC) were performed. In 11 patients (Group 1), transplantation was performed without the use of cryofreezing of the obtained HSCC and 20 auto-HSCCs (Group 2) with freezing according to standard protocols.

Aims: Elimination of toxicity from DMSO during autotransplantation in patients with multiple myeloma.

Methods: The stem cells obtained by apheresis on the Teruma "Spectra Optia" apparatus were stored for 48 hours at a temperature of +4 - +8 C in the refrigerator. Group 2 underwent HSC autotransplantation with DMSO freezing at -90C, which were stored for 1-2 months. The number of CD 34+ cells was determined by flow cytometry on a BD FACS Calibur apparatus using Beckman Coulter reagents (USA)

Results: When collecting HSCs in both groups, CD 34+ averaged 5.3x106 cells/ml, stem cell viability was 100%, and 48 hours later, stem cell viability before transfusion in patients of group 1 was 95%, in group 2, after defrosting after 2 months, it was 99%. During autotransplantation of the 1st group of patients, there were no undesirable manifestations from the entry of DMSO into the patient's blood (signs of cardiorespiratory toxicity and allergic reactions). The absence of toxic complications contributed to the reduction of bed-days in the sterile ward, and averaged 18 days. In group 2, during auto-HSC, an increase in blood pressure was recorded - in 85% of cases, a decrease in SPO2 - in 55%, nausea in 100% of patients, vomiting - in 20% of cases. Bed-days amounted to 24 days.

Conclusion(s):

Conclusion: The use of HSC without freezing improves the results of clinical tolerability, while the viability of stem cells enters the target normative values (90-99%), and also reduces the number of bed-days spent in the hospital, which determines its economic efficiency.